| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA872: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (CDF review of TA559) |
|
Medicine details |
|
| Medicine name | axicabtagene ciloleucel (Yescarta®) |
| Formulation | dispersion for infusion |
| Reference number | 590 |
| Indication | Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma, after two or more lines of systemic therapy |
| Company | Kite Pharma, Inc |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 08/08/2018 |
| NICE guidance | |